These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 35850521)
1. Seroprevalence of SARS-CoV-2 antibodies in the county town of Slovakia - a pilot study from the Trencin city. Kajanova I; Grossmannova K; Jelenska L; Lukacikova L; Radikova Z; Knutova N; Nahlikova J; Belisova M; Pastorekova S; Kopacek J Acta Virol; 2022; 66(3):228-237. PubMed ID: 35850521 [TBL] [Abstract][Full Text] [Related]
2. Seroprevalence of SARS-CoV-2 IgG antibodies in the staff of the Slovak Academy of Sciences in response to COVID-19 and/or vaccination: situation in August 2021. Kajanova I; Lukacikova L; Jelenska L; Grossmannova K; Radikova Z; Vlcek M; Klempa B; Kollar R; Bodova K; Kopacek J; Pastorekova S Acta Virol; 2021; 65(4):420-432. PubMed ID: 34796716 [TBL] [Abstract][Full Text] [Related]
3. Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021. Tunheim G; Rø GØI; Chopra A; Aase A; Kran AB; Vaage JT; Lund-Johansen F; Hungnes O Influenza Other Respir Viruses; 2022 Nov; 16(6):1004-1013. PubMed ID: 35770841 [TBL] [Abstract][Full Text] [Related]
4. A Cell-Based ELISA to Improve the Serological Analysis of Anti-SARS-CoV-2 IgG. Zarletti G; Tiberi M; De Molfetta V; Bossù M; Toppi E; Bossù P; Scapigliati G Viruses; 2020 Nov; 12(11):. PubMed ID: 33171590 [TBL] [Abstract][Full Text] [Related]
5. Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves. Boon SS; Wong MCS; Ng RWY; Leung DTM; Chen Z; Lai CKC; Ho WCS; Huang J; Wong BKC; Fung KSC; Chan PKS JAMA Netw Open; 2021 Nov; 4(11):e2132923. PubMed ID: 34779848 [TBL] [Abstract][Full Text] [Related]
6. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?]. Alessi D; Borré S; Barale A; Isabella A; Milano F; Rossi MA; Silano V; Piu N; Cena T; Faggiano F; Epidemiol Prev; 2020; 44(5-6 Suppl 2):200-206. PubMed ID: 33412811 [TBL] [Abstract][Full Text] [Related]
7. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19? Scaggs Huang F J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545 [TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey. Hoballah A; El Haidari R; Siblany G; Abdel Sater F; Mansour S; Hassan H; Abou-Abbas L BMC Infect Dis; 2022 Jan; 22(1):42. PubMed ID: 35012464 [TBL] [Abstract][Full Text] [Related]
9. Dengue and COVID-19 Co-Circulation in the Peruvian Amazon: A Population-Based Study. Pons MJ; Mayanga-Herrera A; Ulloa GM; Ymaña B; Medina S; Alava F; Álvarez-Antonio C; Meza-Sánchez G; Calampa C; Casanova W; Carey C; Rodríguez-Ferrucci H; Morrison AC; Quispe AM Am J Trop Med Hyg; 2023 Jun; 108(6):1249-1255. PubMed ID: 37094790 [TBL] [Abstract][Full Text] [Related]
10. Enhanced surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic. Dickson E; Palmateer NE; Murray J; Robertson C; Waugh C; Wallace LA; Mathie L; Heatlie K; Mavin S; Gousias P; Von Wissman B; Goldberg DJ; McAuley A Public Health; 2021 Jan; 190():132-134. PubMed ID: 33453689 [TBL] [Abstract][Full Text] [Related]
11. Seroprevalence of SARS-CoV-2 immunoglobulin G antibody during COVID-19 pandemic in Fayoum District, Egypt: a community-based pilot survey. Bakr S; Ezzat EM; Salem KM; Masoud M; Abdelaziz HEM Pan Afr Med J; 2023; 45():22. PubMed ID: 37521757 [TBL] [Abstract][Full Text] [Related]
12. Assessment of initial SARS-CoV-2 seroprevalence in the most affected districts in the municipality of São Paulo, Brazil. Tess BH; Granato CFH; Alves MCGP; Pintão MCT; Nunes MC; Rizzatti EG; Reinach FC Braz J Infect Dis; 2021; 25(4):101604. PubMed ID: 34416142 [TBL] [Abstract][Full Text] [Related]
13. Changes in SARS-CoV-2 seroprevalence and population immunity in Finland, 2020-2022. Solastie A; Nieminen T; Ekström N; Nohynek H; Lehtonen L; Palmu AA; Melin M Emerg Microbes Infect; 2023 Dec; 12(2):2222849. PubMed ID: 37289188 [TBL] [Abstract][Full Text] [Related]
14. Longitudinal change in SARS-CoV-2 seroprevalence in 3-to 16-year-old children: The Augsburg Plus study. Leone V; Meisinger C; Temizel S; Kling E; Gerstlauer M; Frühwald MC; Burkhardt K PLoS One; 2022; 17(8):e0272874. PubMed ID: 35951611 [TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2-Specific Antibody Detection for Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence. den Hartog G; Schepp RM; Kuijer M; GeurtsvanKessel C; van Beek J; Rots N; Koopmans MPG; van der Klis FRM; van Binnendijk RS J Infect Dis; 2020 Oct; 222(9):1452-1461. PubMed ID: 32766833 [TBL] [Abstract][Full Text] [Related]
16. Riding high: seroprevalence of SARS-CoV-2 after 4 pandemic waves in Manitoba, Canada, April 2020-February 2022. Duong S; Burtniak J; Gretchen A; Mai A; Klassen P; Wei Y; Loeppky C; Shaw SY; Bullard J; Van Caeseele P; Stein DR BMC Public Health; 2023 Dec; 23(1):2420. PubMed ID: 38053033 [TBL] [Abstract][Full Text] [Related]
17. Evaluating immunity to SARS-CoV-2 in nursing home residents using saliva IgG. Katz MJ; Heaney CD; Pisanic N; Smith L; Bigelow BF; Sheikh F; Boudreau A; Kruczynski K; Hsu YJ; Salinas AB; Cosgrove SE; Rock C J Am Geriatr Soc; 2022 Mar; 70(3):659-668. PubMed ID: 35038344 [TBL] [Abstract][Full Text] [Related]
18. The Seroprevalence of SARS-CoV-2 in Children During Early COVID-19 Pandemic in Korea: A Nationwide, Population-Based Study. Lee J; Choe YJ; Minn D; Kim JH J Korean Med Sci; 2022 Nov; 37(44):e314. PubMed ID: 36377292 [TBL] [Abstract][Full Text] [Related]
19. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection. Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM Elife; 2022 Jan; 11():. PubMed ID: 35072628 [TBL] [Abstract][Full Text] [Related]
20. The level of protective post-vaccination antibodies in NIPH-NIH employees after administration of Pfizer vaccine against COVID-19. Rastawicki W; Płaza K Przegl Epidemiol; 2021; 75(1):3-13. PubMed ID: 34328282 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]